ClinicalTrials.gg
CompletedNCT06916273Updated Dec 30, 2025

Safety, Tolerability, and Pharmacokinetics of PA9159 Inhalation Aerosol in Healthy Adult Subjects

A Phase 1 interventional study of PA9159 Inhalation aerosol, 60 μg one day treatment and PA9159 Inhalation aerosol, 120 μg one day treatment in Bronchial Asthma, sponsored by Anhui Palo Alto Pharmaceuticals, Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Anhui Palo Alto Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jul 2024, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Enrollment
154th of 182
40 · median 203
Started
2024
with 37 others
Phase 1
31 of 251
3 open now
Registered
201st of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 154th largest by enrollment of the 182 interventional ones that give a count, is one of 38 that started in 2024, is one of 31 in phase 1, and was the 201st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of Inhalation aerosol PA9159, to establish maximum tolerated dose in healthy chinese adult

Read the detailed description

This is a randomized, double-blind, placebo-controlled dose escalation phase 1 trial, including single dose and 7-day repeat doses of PA9159 Inhalation aerosol. In the first part of the study, the treatment is given once for one day, with escalation doses of 60 μg, 120 μg, 240 μg, 300 μg. 30 health subjects will be enrolled for this part. In the second part of the study, PA9159 at the escalation dose of 120 μg is given twice a day for 7 days. 10 health subjects will be enrolled for this group, randomized proportionally at 4:1 ratio to receive either the investigational product PA9159 Inhalation aerosol or placebo , with a total of 40 subjects for this two-part study. Subjects will be evaluated for the safety, tolerability and pharmacokinetics of PA9159 Inhalation aerosol.

03

Conditions studied

  • Bronchial Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 18 to 65 years (including upper and lower limits);
  • Male body weight ≥ 50 kg, female weight ≥ 45 kg, (BMI) between 19 and 26 kg/m2 (including cut-off values);
  • Voluntary participation and signing of .

Exclusion criteria

Exclusion Criteria:

  • Those who cannot use the nebulizer correctly, cannot tolerate nebulized inhalation administration or have failed the training for inhalation administration;
  • Those with special dietary requirements and cannot follow the unified diet;
  • Those with a history of chronic diseases such as cardiovascular, digestive, endocrine, hematological, immune, and nervous system diseases; those with chronic diseases of the oral, pharyngeal, and respiratory systems; those with chronic diseases of the oral, pharyngeal, and respiratory systems at the time of screening; those with a history of recurrent (defined as more than 1 episode) or disseminated herpes zoster, repeated infection, tuberculosis infection, glaucoma, or cataract;
  • Those who are allergic to the study drug or any component of the study drug, or have an allergic constitution (referring to an allergic constitution to more than two drugs and foods);
  • Those whose vital signs, physical examination, laboratory tests, chest X-ray examination, 12-lead examination, pulmonary ventilation function examination, etc. at the screening period are judged abnormal and have clinical significance;
  • Those with positive tests for surface antigen (HBsAg), virus antibody (HCV Ab), Treponema pallidum antibody (Syphilis TP), (HIV Ag/Ab);
  • Those with ≤ 80% of predicted value or FVC ≤ 80% of predicted value at the screening period;
  • Those who frequently drink alcohol within 3 months before screening, that is, those who drink more than 14 units of alcohol per week (1 unit = 360 mL of beer with 5% alcohol content or 45 mL of spirits with 40% alcohol content or 150 mL of wine with 12% alcohol content) or those with positive alcohol breath test at the screening period or those who cannot stop alcohol intake during the study period;
  • Those with a smoking history of more than 10 years and smokers within 3 months before screening, or those who cannot stop using any tobacco products during the trial, or those with positive nicotine detection at the baseline period.
  • Those who have a history of drug abuse or drug use within the past two years, or those whose urine screening for drug abuse is positive;
  • Those who have taken any drugs (prescription drugs, over-the-counter drugs, Chinese herbal medicines, vaccines) or health supplements within the two weeks prior to screening or during the screening period;
  • Those who have used any preparations containing components or any drugs that affect the activity of enzymes (such as ritonavir or ketoconazole, etc., as detailed in Appendix 5) within the 30 days prior to screening or during the screening period;
  • Those who have consumed beverages or foods containing grapefruit, dragon fruit, mango, pomelo, pomegranate, papaya, or rambutan within 14 days prior to screening or during the screening period, or those who do not agree to stop consuming the above foods during the trial period;
  • Those who have consumed any foods or beverages rich in caffeine, xanthine within 48 hours before the first use of the study drug (coffee, tea, cola, chocolate, seafood, animal liver, etc.), or those who do not agree to stop consuming the above foods during the trial period;
  • Those who have donated blood or suffered significant blood loss within 90 days prior to screening or during the screening period (≥ 400 mL, except during the menstrual period of women) or have received blood products or undergone blood transfusion;
  • Those who have participated in other clinical trials within 90 days prior to screening and have used the study product;
  • Those who have undergone respiratory surgery in the past, or those who have undergone major surgery within 3 months prior to screening (judged by the investigator based on the previous medical history), suffered major trauma or planned to undergo surgery during the trial period;
  • Those who have difficulty in venous blood collection, or have a known history of multiple fainting or hematemesis;
  • Female subjects who have tested positive for pregnancy detection or are in lactation during the screening period or baseline period;
  • Subjects who, in the opinion of the investigator, have other conditions that are not suitable for participating in the trial or who cannot participate in the trial due to their own reasons.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    PA9159 60 μg single dose and placebo

    Six subjects will be randomly assigned at a 2:1 ratio to receive either single dose of 60 μg PA9159 or placebo. Before escalating to the next dose level, all available clinical and laboratory safety data will be reviewed.

    Drug: PA9159 Inhalation aerosol, 60 μg one day treatment · Drug: Placebo, the same Inhalation aerosol solution without PA9159 active ingredient

  • Experimental
    PA9159 120 μg single dose and placebo

    Eight subjects will be randomly assigned in a 3:1 ratio to receive either single dose of 120 μg PA9159 or placebo. Before escalating to the next dose level, all available clinical and laboratory safety data will be reviewed.

    Drug: PA9159 Inhalation aerosol, 120 μg one day treatment · Drug: Placebo, the same Inhalation aerosol solution without PA9159 active ingredient

  • Experimental
    PA9159 240 μg single dose and placebo

    Eight subjects will be randomly assigned in a 3:1 ratio to receive either single dose of 240 μg PA9159 or placebo. Before escalating to the next dose level, all available clinical and laboratory safety data will be reviewed.

    Drug: PA9159 Inhalation aerosol, 240 μg one day treatment · Drug: Placebo, the same Inhalation aerosol solution without PA9159 active ingredient

  • Experimental
    PA9159 300 μg single dose and placebo

    Eight subjects will be randomly assigned in a 3:1 ratio to receive either single dose of 300 μg PA9159 or placebo. all available clinical and laboratory safety data will be reviewed.

    Drug: PA9159 Inhalation aerosol, 300 μg one day treatment · Drug: Placebo, the same Inhalation aerosol solution without PA9159 active ingredient

  • Experimental
    PA9159 120 μg repeated doses and placebo

    Ten subjects will be randomly assigned at a 4: 1 ratio to receive either 120 μg PA9159 or placebo twice a day for 7 days. all available clinical and laboratory safety data will be reviewed.

    Drug: PA9159 Inhalation aerosol, 120 μg 7-day treatment · Drug: Placebo, the same Inhalation aerosol solution without PA9159 active ingredient

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects experiencing adverse events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical study subject administered a medicinal product which does not necessarily have a causal relationship with this treatment.

    Time frame: within 48 hours after last treatment

  2. Number of subjects having abnormal hematology laboratory parameters

    Absolute and relative number of subjects with values below, within or above the normal range will be assessed.

    Time frame: within 48 hours after last treatment

  3. Number of subjects with abnormal clinical chemistry parameters

    Absolute and relative number of subjects with values below, within or above the normal range will be assessed.

    Time frame: within 48 hours after last treatment

  4. Number of subjects with abnormal values for urinalysis

    Absolute and relative number of subjects with values below, within or above the normal range will be assessed.

    Time frame: within 24 hours after last treatment

  5. Systolic and diastolic blood pressure

    Vital sign-Systolic and diastolic blood pressure

    Time frame: within 48 hours after last treatment

  6. ECG parameter-QTc interval

    A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically calculates the QTc intervals

    Time frame: up to 24 hours after last treatment

  7. Body temperature

    Vital sign-Body temperature

    Time frame: within 48 hours after last treatment

  8. Pulse rate

    Vital sign-Pulse rate

    Time frame: within 48 hours after last treatment

  9. ECG parameter-PR interval

    A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures PR intervals

    Time frame: up to 24 hours after last treatment

  10. ECG parameter-QRS duration

    A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures QRS duration

    Time frame: up to 24 hours after last treatment

Secondary outcomes

  1. Serum cortisol levels

    Monitor the concentration changes of serum cortisol before and after PA9159 administration.

    Time frame: From pre-dose until 24 hours post-dose

  2. Pharmacokinetics of single dose and repeat doses of inhalation aerosol PA9159

    Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter (Cmax)

    Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects)5, 10, 15, 30 minutes, 1, 1.5, 2, 3 , 4, 6, 8,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6

  3. Pharmacokinetics of single dose and repeat doses of inhalation aerosol PA9159

    Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter (Tmax)

    Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects)5, 10, 15, 30 minutes, 1, 1.5, 2, 3 , 4, 6, 8,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6

  4. Pharmacokinetics of single dose and repeat doses of inhalation aerosol PA9159

    Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter (AUC)

    Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects)5, 10, 15, 30 minutes, 1, 1.5, 2, 3 , 4, 6, 8,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6

  5. Pharmacokinetics of single dose and repeat doses of inhalation aerosol PA9159

    Blood samples will be collected serially, and the concentrations of PA9159 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter (T1/2)

    Time frame: Pre-dose, and post-dose (day 1 for single dose subjects, day 1 and day 7 for repeat doses subjects)5, 10, 15, 30 minutes, 1, 1.5, 2, 3 , 4, 6, 8,12, 24 hours, and for repeat doses subjects, also 30 minutes pre-dose on day 4, day 5 and day 6

07

Study locations

1 site
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Sep 2024, 1 month.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 1 month is below that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Apr 8, 2025
StartActual
Jul 22, 2024
Primary completionActual
Sep 12, 2024
CompletionActual
Sep 21, 2024
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06916273
Lead sponsor
Anhui Palo Alto Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Jul 22, 2024
Primary completion
Sep 12, 2024
Completion
Sep 21, 2024
Last update
Dec 30, 2025

Study contacts

Jinhua Wen, phD
principal investigator · The First Affiliated Hospital of Nanchang University
Xiaohua Cheng, Master
principal investigator · The First Affiliated Hospital of Nanchang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PA9159

Start the discussion